GO
Loading...

Enter multiple symbols separated by commas

Mylan Inc

More

  • NEW YORK/ LONDON, June 29- Mergers and acquisitions worldwide in the second quarter of 2015 almost matched the record set in the second quarter of 2007, according to preliminary Thomson Reuters data, as big companies turned to deals to boost their market share. These include Royal Dutch Shell Plc's $70 billion acquisition of British rival BG Group Plc, cable...

  • TEL AVIV, June 23- Mylan NV chief financial officer John Sheehan will arrive in Israel on Wednesday for a meeting with the head of the Tel Aviv Stock Exchange to discuss a possible listing of its shares if it succeeds in buying Perrigo Co, an industry source said. Mylan has offered to acquire Perrigo for $34 billion in an attempt to fend off a bid from Israel's Teva...

  • NEW YORK, June 18- A U.S. appeals court on Thursday once again invalidated a patent held by Teva Pharmaceutical Industries Ltd on its top-selling multiple sclerosis drug Copaxone, clearing the way for the launch of a cheaper, generic version. The decision, by the U.S. Court of Appeals for the Federal Circuit, the nation's top patent tribunal, was a blow to Israel's...

  • June 16- Mylan NV's largest stakeholder, Abbott Laboratories, said it would back Mylan's proposed acquisition of Perrigo Co Plc, potentially helping Mylan fend of interest from Teva Pharmaceutical Industries Ltd. Abbott, which has a 14.5 percent stake in Mylan, said on Tuesday that it supported Mylan's "standalone strategy" and believed acquiring Perrigo...

  • Abbott to vote for Mylan's acquisition of Perrigo Tuesday, 16 Jun 2015 | 9:20 AM ET

    June 16- Abbott Laboratories said it would vote its 14.5 percent stake in Mylan NV in favor of Mylan's proposed acquisition of Perrigo Company Plc. Mylan's latest offer for Perrigo, worth $34.1 billion, is widely seen as an attempt to fend off Teva Pharmaceutical Industries Ltd, the world's biggest maker of generic drugs. Abbott, Mylan's largest shareholder, said...

  • More than a third of India's 2.1 million HIV/AIDS patients depend on getting their daily antiretrovirals for free from state-run distribution centres, but many of them have been facing shortages or stock outs for months. The notice put out by the Central Board of Excise and Customs this week intends to make it cheaper to import raw materials that are used to...

  • UPDATE 1-Teva switches legal counsel after Mylan challenge Wednesday, 10 Jun 2015 | 12:41 AM ET

    June 9- Teva Pharmaceutical Industries Ltd has changed the law firm it had tapped for advice on its $40 billion attempt to take over smaller rival Mylan NV after a court sided with the latter's bid to seek a preliminary injunction against the previous law firm. Teva is now working with Sullivan& Cromwell LLP as legal counsel in its proposal to acquire Mylan, the...

  • AMSTERDAM, June 8- Executives at Israeli drugmaker Teva sent an open letter to takeover target Mylan on Monday, saying they remain committed to a deal and reiterated that Teva's $40 billion takeover proposal would benefit shareholders of both firms. In the letter, addressed to Mylan executive founder Robert Coury, Teva CEO Erez Vigodman and Chairman Yitzhak...

  • Your first trade for Thursday Wednesday, 3 Jun 2015 | 6:41 PM ET
    Fast Money Final Trade:  COST, NXPI, RNF & SAVE

    The "Fast Money" traders give their final trades of the day.

  • Teva raises stake in Mylan Wednesday, 3 Jun 2015 | 9:15 AM ET
    Teva raises stake in Mylan

    Teva is poised to raise its stake in Mylan as it pursues its takeover bid. - Reuters

  • Early movers: EXPE, LNKD, DIS, GES, HPQ & more Wednesday, 3 Jun 2015 | 7:54 AM ET
    Trader on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Teva poised to raise its stake in Mylan: Report Wednesday, 3 Jun 2015 | 7:07 AM ET
    Mylan headquarters Canonsburg, Pennsylvania

    Teva Pharmaceutical is looking to buy more shares in Mylan, positioning itself for a possible legal challenge to the generics drugmaker.

  • These are the best stocks from now to October Tuesday, 2 Jun 2015 | 10:56 AM ET
    Healthcare

    Since 1990 this stock sector has risen 5.2 percent. It's outperformed the broader market 65 percent of the time from May to October.

  • Early movers: MDT, PVH, DG, SHLD, AAPL & more Tuesday, 2 Jun 2015 | 7:48 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • June 1- Mylan NV said Teva Pharmaceutical Industries Ltd, which has made an unsolicited offer for the company, violated U.S. anti-trust rules by acquiring a stake. Teva disclosed a 1.35 percent stake in Mylan last week. Mylan said on Monday there was still no clarity whether Teva would make a formal offer, almost six weeks since Teva's offer for about $40 billion.

  • This stock is no longer in the Top 20 most held Friday, 29 May 2015 | 11:51 AM ET
    Traders work on the floor of the New York Stock Exchange.

    New data provided to CNBC from eVestment shows the most popular stocks held by institutional funds.

  • Early movers: BRCM, COST, EXPR, ANF & more Thursday, 28 May 2015 | 7:52 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • After-hours buzz: Palo Alto, Teva, Analog & more Wednesday, 27 May 2015 | 5:30 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Check out the companies making headlines after the bell Wednesday: Palo Alto, Teva, Analog Devices & more.

  • Teva discloses 1.35 pct stake in target Mylan Wednesday, 27 May 2015 | 4:42 PM ET

    May 27- Teva Pharmaceutical Industries Ltd disclosed a 1.35 percent interest in Mylan NV, saying the purchase underscored its commitment to buy Mylan as soon as possible. Teva proposed to buy Mylan for $82 per share, or about $43 billion, in cash and stock last month. Mylan rejected the offer saying it "grossly undervalued" the company, setting up a three-way battle...

  • Here's how to play weak Q2 earnings season Monday, 18 May 2015 | 7:39 AM ET
    Delta Airlines planes sit at Terminal 4 at John F. Kennedy Airport in New York.

    Negative revenue growth will continue to dog investors in Q2 and Q3, analyst Mike Thompson says. Here's what to do about it.